Stonebrook Private Inc. Has $332,000 Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Stonebrook Private Inc. cut its position in DexCom, Inc. (NASDAQ:DXCM) by 13.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,264 shares of the medical device company’s stock after selling 638 shares during the period. Stonebrook Private Inc.’s holdings in DexCom were worth $332,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in DXCM. Geode Capital Management LLC boosted its stake in DexCom by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company’s stock valued at $775,256,000 after purchasing an additional 56,094 shares during the last quarter. Jennison Associates LLC boosted its stake in DexCom by 10.3% during the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after purchasing an additional 710,858 shares during the last quarter. Norges Bank acquired a new position in DexCom during the 4th quarter valued at about $385,367,000. Northern Trust Corp boosted its stake in DexCom by 22.2% during the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company’s stock valued at $322,454,000 after purchasing an additional 753,857 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in DexCom by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company’s stock valued at $219,716,000 after purchasing an additional 91,051 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have issued reports on DXCM. Morgan Stanley lifted their price target on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Citigroup lifted their price target on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Canaccord Genuity Group boosted their target price on DexCom from $103.00 to $106.00 and gave the stock a “buy” rating in a research note on Friday, May 2nd. Finally, Mizuho initiated coverage on DexCom in a research note on Thursday, April 10th. They issued an “outperform” rating and a $85.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.11.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 14,076 shares of the company’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the transaction, the chief operating officer now owns 313,497 shares of the company’s stock, valued at approximately $22,063,918.86. This represents a 4.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 32,498 shares of the company’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares in the company, valued at approximately $26,183,401.02. The trade was a 8.03% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 66,926 shares of company stock worth $4,734,384 over the last 90 days. Corporate insiders own 0.32% of the company’s stock.

DexCom Trading Down 0.2%

NASDAQ:DXCM opened at $85.48 on Friday. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $33.52 billion, a PE ratio of 59.78, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43. The firm’s 50 day moving average is $72.01 and its 200 day moving average is $77.64. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $132.09.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The company’s revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.32 EPS. Sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.